Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new targets for antibody-based cancer treatments with an upfront payment of $36 million.
Axsome Therapeutics said the lower dose of its sleep disorder drug Sunosi met the primary endpoint in a late-stage test of adults with ADHD. But Wall Street analysts noted that less impressive results for its higher dose leave room for uncertainty about the company's label expansion prospects.
Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients with a challenging form of ovarian cancer, sending its shares up 76% at market open on Monday.
Novo Nordisk invests $1.05B in Brazil factory to boost GLP-1 drug production, including Wegovy and Ozempic, creating 600 jobs by 2028 in Montes Claros.
DHL Group investing €2B in healthcare/life sciences, AGC Biologics adds bioreactors in Japan, OXB reports revenue growth, plus updates from Sai Life Sciences, Curium, SHINE, Lonza & Asahi Kasei.
Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup
Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.
Aldeyra Therapeutics reports Phase 3 success with reproxalap for dry eye disease, plans third FDA filing after previous rejections. AbbVie partnership remains intact.
Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.
